SEC Info - Stem Cell Inc. - ‘8-K’ for 12/12/23

SEC Info℠

Home

Help

Please Sign In

Stem Cell Inc. – ‘8-K’ for 12/12/23

On: Thursday, 1/11/24, at 6:05am ET · For: 12/12/23 · Accession #: 1477932-24-119 · File #: 0-56400

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 1/11/24  Stem Cell Inc.                    8-K:4,9    12/12/23   13:161K                                   Discount Edgar/FA

Current Report — Form 8-K

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     23K 
 2: EX-16.1     Letter re: a Change in Accountant                   HTML      7K 
 8: R1          Cover                                               HTML     44K 
11: XML         IDEA XML File -- Filing Summary                      XML     12K 
 9: XML         XBRL Instance -- global_8k_htm                       XML     15K 
10: EXCEL       IDEA Workbook of Financial Report Info              XLSX      8K 
 5: EX-101.CAL  XBRL Calculations -- stemcell-20231212_cal           XML      8K 
 7: EX-101.DEF  XBRL Definitions -- stemcell-20231212_def            XML     11K 
 4: EX-101.LAB  XBRL Labels -- stemcell-20231212_lab                 XML     42K 
 6: EX-101.PRE  XBRL Presentations -- stemcell-20231212_pre          XML     28K 
 3: EX-101.SCH  XBRL Schema -- stemcell-20231212                     XSD     19K 
12: JSON        XBRL Instance as JSON Data -- MetaLinks               11±    17K 
13: ZIP         XBRL Zipped Folder -- 0001477932-24-000119-xbrl      Zip     14K

‘8-K’ — Current Report

This is an HTML Document rendered as filed. [ Alternative Formats ]

iX: C:

i 0001828613 i false00018286132023-12-122023-12-12iso4217:USDxbrli:sharesiso4217:USDxbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM i 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 10, 2024 ( i December 12, 2023)

i STEM CELL INC.

(Exact name of registrant as specified in its charter)

i Nevada

i 333-251389

i 84-2834915

(State or other jurisdiction

of Incorporation or organization)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

i 701 North Green Valley Pkwy, i Suite 200

i Henderson, i NV i 89074

(Address of principal executive offices, Zip Code)

( i 702) i 354-8751

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

i ☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

i ☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

i ☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

i ☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: None.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company i ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. i ☐

Item 4.01 Changes in Company's Certifying Accountant

(a) On December 12, 2023, the Registrant’s independent accountant, WWC resigned as the Company’s auditor. WWC’s audit report on the Registrant’s financial statements as of and for the fiscal years ended December 31, 2022 and 2021 did not contain an adverse opinion or a disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope or accounting principles except that such audit report did include an explanatory paragraph regarding the Company’s ability to continue as a going concern.

During the Registrant's two most recent fiscal years, there were no disagreements with WWC on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreement(s), if not resolved to the satisfaction of WWC, would have caused it to make reference to the subject matter of the disagreement(s) in connection with its report.

We furnished a copy of this disclosure to WWC and requested WWC to furnish us with a letter addressed to the Securities and Exchange Commission (the “SEC”) stating whether it agrees with the above statements.

(b) The Registrant is searching for a new certifying accountant and will file an 8-K once an auditor has been retained.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

16.1		Letter
104		Cover Page Interactive Data File (embedded within the Inline XBRL Document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Stem Cell Inc.

Date: January 10, 2024	By:	/s/ *Sam Kwok*
		Name: Sam Kwok
		Title: Chief Executive Officer

Dates Referenced Herein and Documents Incorporated by Reference

This ‘8-K’ Filing	Date	Other Filings

Filed on:	1/11/24
	1/10/24
For Period end:	12/12/23
	12/31/22	10-K, NT 10-K
	12/31/21	10-K
		List all Filings

↑Top

Filing Submission 0001477932-24-000119 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)